Posidiam Extended-Release Tablet 5/1000 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
MFDS item code 202107223 · Approved 2021.10.29
Improvement of glycemic control in adults with type 2 diabetes mellitus
This drug helps improve blood sugar control in adults with type 2 diabetes when dapagliflozin and metformin are administered together. It can be used in conjunction with diet and exercise therapy and is suitable when blood sugar is not adequately controlled. Caution is needed regarding the cardiovascular effects of dapagliflozin, especially in patients with pre-existing cardiovascular diseases or risk factors, thus professional guidance is recommended. This drug effectively improves blood sugar control in patients with type 2 diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior experience of antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse effects of metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, this medicine may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and below 60 mL/min/1.73 m2, with no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).
This drug is used for the treatment of diabetes and should not be administered to patients with poor kidney function or certain severe diseases. This drug can rarely cause a serious metabolic complication known as lactic acidosis, therefore if symptoms or risk factors are present, you should consult your doctor immediately. Additionally, this drug carries a risk of hypoglycemia when used together with insulin or sulfonylurea medications, so blood sugar levels should be monitored closely. For elderly patients with decreased kidney function or those with low fluid volume, kidney function and fluid status should be evaluated before administration, and regular monitoring is necessary during treatment. This drug may cause genital and urinary tract infections in some patients, so treatment should be sought immediately if related symptoms arise. During treatment, excessive alcohol consumption should be avoided, and it is safer not to use in patients with impaired liver function, pregnant women, or nursing mothers. Before and after surgeries or tests using iodinated contrast agents, this medication should be discontinued for a certain period, and it should be restarted only after confirming normal kidney function. This drug may reduce vitamin B12 levels, so regular checks of vitamin B12 levels are recommended during long-term use. In case of overdose, immediately visit a medical institution for appropriate treatment, and this drug's safety and effectiveness have not been established in children. During treatment, dizziness may occur when driving or operating machinery, so caution is necessary. Finally, this medication should be kept out of the reach of children and stored in its original container to prevent quality deterioration.
Not everyone experiences these, and they can vary from person to person.
This drug can be sensitive to air and moisture, so it should be kept in a tightly sealed container. It is preferable to store at room temperature, that is, between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness over time.
Dark pink, biconvex, egg-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.